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Background: There is a lack of consensus regarding the definition of risk factors for healthcare-associated infection
(HCAI). The purpose of this study was to identify additional risk factors for HCAI, which are not included in the
current definition of HCAI, associated with infection by multidrug-resistant (MDR) pathogens, in all hospitalized
infected patients from the community.
Methods: This 1-year prospective cohort study included all patients with infection admitted to a large, tertiary care,
university hospital. Risk factors not included in the HCAI definition, and independently associated with MDR
pathogen infection, namely MDR Gram-negative (MDR-GN) and ESKAPE microorganisms (vancomycin-resistant
Enterococcus faecium, methicillin-resistant Staphylococcus aureus, extended-spectrum beta-lactamase-producing
Escherichia coli and Klebsiella species, carbapenem-hydrolyzing Klebsiella pneumonia and MDR Acinetobacter
baumannii, Pseudomonas aeruginosa, Enterobacter species), were identified by logistic regression among patients
admitted from the community (either with community-acquired or HCAI).
Results: There were 1035 patients with infection, 718 from the community. Of these, 439 (61%) had microbiologic
documentation; 123 were MDR (28%). Among MDR: 104 (85%) had MDR-GN and 41 (33%) had an ESKAPE infection.
Independent risk factors associated with MDR and MDR-GN infection were: age (adjusted odds ratio (OR) = 1.7 and
1.5, p = 0.001 and p = 0.009, respectively), and hospitalization in the previous year (between 4 and 12 months
previously) (adjusted OR = 2.0 and 1,7, p = 0.008 and p = 0.048, respectively). Infection by pathogens from the
ESKAPE group was independently associated with previous antibiotic therapy (adjusted OR = 7.2, p < 0.001) and a
Karnofsky index <70 (adjusted OR = 3.7, p = 0.003). Patients with infection by MDR, MDR-GN and pathogens from
the ESKAPE group had significantly higher rates of inadequate antibiotic therapy than those without (46% vs 7%,
44% vs 10%, 61% vs 15%, respectively, p < 0.001).
Conclusions: This study suggests that the inclusion of additional risk factors in the current definition of HCAI for
MDR pathogen infection, namely age >60 years, Karnofsky index <70, hospitalization in the previous year, and
previous antibiotic therapy, may be clinically beneficial for early diagnosis, which may decrease the rate of
inadequate antibiotic therapy among these patients.
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Traditionally, infections have been classified as commu-
nity or hospital-acquired, according to their place of ac-
quisition, and this classification is still used to guide
diagnosis and treatment of infections [1,2]. However, an
increasing number of patients reside in nursing homes,
the use of aggressive medical therapies (intravenous
therapy, wound dressing) at home is more common, an
increasing number of invasive therapies (hemodialysis,
chemotherapy, radiotherapy) are performed in out-
patient clinics, and there is a greater population of older
patients, with more chronic diseases and frequent
utilization of medical resources. This has led to the cre-
ation of a new group among the traditional classification
of infections, termed “healthcare-associated infections”
(HCAI).
In 2002, Deborah Friedman and colleagues [3] pro-
posed a definition of HCAI including the above sub-
groups of patients, but despite being widely used in
clinical studies [4-9], there is a lack of consensus regard-
ing risk factors, and more recent studies have included
additional risk factors such as an immunocompromised
state, hospitalization in the previous year and prior anti-
biotic therapy [5,10]. Unfortunately, most of the studies
performed using the HCAI classification have been
restricted to respiratory infections [4,5,8,10], blood-
stream infections [3,6,11] or a single pathogenic agent
[7,9,12], creating the need to widen the study of risk fac-
tors for infection by multidrug-resistant (MDR) patho-
gens to all infected patients hospitalized from the
community.
The objective of this study was to identify additional
risk factors associated with infection by MDR pathogens
in all infected patients admitted from the community
into the hospital setting (patients with community-
acquired and HCAI, including all foci of infection and
associated pathogens), and not included in the adopted
definition of HCAI [3].Methods
Study design and patient population
A prospective cohort study was conducted in a 600-bed
tertiary care university hospital, over a 1-year period (1
June 2008 to 31 May 2009). All consecutive adult
infected patients admitted to the medical, surgical, neph-
rology or hematology wards of the hospital, or to the in-
tensive care unit (ICU) were included, based on a
diagnosis of infection according to the Center for Dis-
ease Control (CDC) criteria [1]. The primary outcome of
interest was infection by a MDR pathogen. All patients
completed the follow-up until hospital discharge. This
study was approved by the Institutional Review Board of
Hospital de Santo António, Oporto Hospital Centre,Portugal, and informed consent was waived owing to the
observational nature of the study.
Definitions
Community-acquired infection (CAI) was defined as an
infection detected within 48 h of hospital admission in
patients who did not fit the criteria for a HCAI.
HCAI was defined using the same criteria of Friedman
et al. [3]-an infection present at the time of hospital ad-
mission or within 48 h of admission in patients that ful-
filled any of the following criteria:
– received intravenous therapy at home; received
wound care or specialized nursing care through a
healthcare agency, family or friends; or self-
administered intravenous medical therapy in the 30-
day period before the onset of the infection;
– attended a hospital or hemodialysis clinic, or
received intravenous chemotherapy in the previous
30 days;
– hospitalized in an acute care hospital for 2 or more
days in the previous 90 days;
– resided in a nursing home or long-term care facility.
Hospital-acquired infection (HAI) was defined as a
localized or systemic condition that resulted from an ad-
verse reaction to the presence of an infectious agent(s)
or its toxin(s), and that occurred 48 h or more after hos-
pital admission and was not incubating at the time of
admission [1]. Infections in patients recently discharged
from hospital within the previous 2-week period were
also included in this group.
The CDC definitions were used to define infections at
different anatomic sites [1]. The definition of MDR organ-
isms used was adopted from the CDC recommendations
for the management of MDR organisms in healthcare set-
tings that defines MDR organisms as bacteria that are re-
sistant to one or more classes of antimicrobial agents
recommended as first line therapy [13]. Thus, enteric
Gram-negative rods were considered MDR (MDR-GN) if
they were resistant to amoxicillin-clavulanate, piperacillin-
tazobactam, carbapenems, aztreonam, fluoroquinolones,
or third-generation cephalosporins or aminoglycosides.
Acinetobacter spp. and Pseudomonas spp. were considered
MDR if they were resistant to piperacillin-tazobactam,
imipenem/meropenem, aztreonam, ciprofloxacin, cefe-
pime, ceftazidime, aminoglycosides or colistin.
We grouped vancomycin-resistant Enterococcus fae-
cium, methicillin-resistant Staphylococcus aureus (MRSA),
extended-spectrum beta-lactamase (ESBL)-producing
Escherichia coli and Klebsiella species, carbapenem-
hydrolyzing Klebsiella pneumonia and MDR Acinetobac-
ter baumannii, Pseudomonas aeruginosa and Enterobacter
species into a group denominated ESKAPE, according to
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of America [14].
The presence of ESBL production among E. coli and
Klebsiella spp. strains was screened by the automatic
analyzer Vitek2 (bioMérieux, France). It was confirmed
by a disk diffusion test that detects synergism between
the cephalosporins/monobactam and clavulanate. If the
interpretation of the results was doubtful, we also per-
formed the EtestW (AB Biodisk, Solna, Sweden); a com-
bination of cefotaxime and cefotaxime/clavulanate and
ceftazidime and ceftazidime/clavulanate indicated ESBL
production whenever the ESBL ratio with antibiotic:anti-
biotic+inhibitor was ≥8.
The presence of carbapenemase production in Entero-
bacteriaceae was suspected whenever minimum inhibitory
concentrations for ertapenem, imipenem and meropenem
exceeded 0.5, 1 and 1 μg/mL, respectively. In such cases, a
modified Hodge test was performed, and the ultimate
confirmatory test was carbapenemase detection by mo-
lecular methods.
The risk factors studied for association with infection by
MDR pathogens (including MDR-GN and the ESKAPE
group) included age, sex, previous antibiotic therapy (in
the last month prior to the current infection), previous
hospitalization (in the last 12 months prior to the current
infection, but not in the last 3 months), patient comorbid-
ities and general medical condition. The comorbidities
studied included immunosuppression (administration of
radiation therapy in the 12 months prior to hospital admis-
sion, administration of 0.2 mg/kg/day of prednisolone for
at least 3 months prior to hospital admission, administra-
tion of 1 mg/kg/day of prednisolone for 1 week in the
3 months prior to hospital admission or infection with
human immunodeficiency virus), chronic liver disease [15],
chronic heart failure [15], chronic respiratory disease [15],
hematological disease [16], cancer (metastatic disease not
under chemotherapy in the previous 12 months), diabetes
mellitus requiring insulin therapy or oral hypoglycemic
agents before the infection and/or atherosclerosis (defined
as a previous history of a transient ischemic attack, stroke,
angina, myocardial infarction or peripheral arterial disease).
The patient’s general medical condition was assessed by
the Karnofsky index [17]. A score of lower than 70 implies
that the patient is unable to perform normal activities or
do active work.
Adequacy of initial antibiotic therapy, hospital length
of stay, Simplified Acute Physiology Score (SAPS II) and
hospital mortality were also compared between groups
of patients with and without infection by MDR patho-
gens (MDR-GN and ESKAPE). The initial empirical
antibiotic treatment was considered “adequate” if the re-
sponse to the initial antibiotic prescribed within 24 h of
diagnosis matched in vitro susceptibility of the pathogen
deemed to be the likely cause of the infection, and whenthe dosage and route of administration were appropriate
for the patient’s current medical status (focus and sever-
ity of infection); only patients with positive microbiology
were considered in this analysis. SAPS II [16] was
recorded on the first day of antibiotic therapy.
Statistical analysis
Continuous variables are described as mean and stand-
ard deviation (SD), or as median and inter-quartile range
if they showed a skewed distribution. Categorical vari-
ables are described with absolute frequencies and
percentages. Comparison of demographic and clinical
characteristics of infected patients from the community
(either with CAI or HCAI) and patients with HAI was
made using the Student t-test (for continuous variables
with normal distribution), the Mann–Whitney U test
(for continuous variables with skewed distribution) and
the Pearson χ2 test (for categorical variables).
Comparison of inadequate antibiotic therapy, hospital
length of stay, SAPS II and hospital mortality between the
group of patients infected with MDR pathogens and those
not infected, along with comparison of the group infected
by MDR-GN with those not infected, and the group
infected by ESKAPE pathogens and those not infected,
was made with the same tests according to the type of
variables compared (continuous with normal distribution,
continuous with skewed distribution or categorical).
All variables potentially associated with MDR pathogen
infection (including MDR-GN and ESKAPE pathogens)
were studied among all infected patients admitted from
the community, those with CAI and HCAI, and included:
age, sex, previous antibiotic therapy, hospitalization in the
previous year, immunosuppression, chronic hepatic dis-
ease, chronic heart failure, chronic respiratory disease,
chronic hematologic disease, cancer, diabetes, atheroscler-
osis and decreased functional capacity (Karnofsky index
<70). Those with a clear association in the univariate ana-
lysis (p < 0.1) were included in the multivariable analysis.
The results of the multivariable models are expressed as
odds ratio (OR) with 95% confidence interval and p-
values. The calibration was tested using the Hosmer-
Lemeshow goodness-of-fit test. The significance level was
defined as p < 0.05. Data were analyzed using SPSS ver-
sion 18 for Windows (SPSS Inc., Chicago, IL, USA).
Results
During the study period a total of 3733 patients were
assessed and 1035 (28%) met the inclusion criteria of having
infection according to the CDC definitions of infection. The
mean ± SD age of the patients included was 65 ± 20 years,
and the mean SAPS II was 29 ± 13; 49% of patients were
male, and the overall hospital mortality rate was 13%
(Table 1). Of these, 718 were admitted to hospital from the
community with infection: 493 (48%) with a CAI and 225
Table 1 Demographic and clinical characteristics of patients, according to place of acquisition of infection
Patients’ characteristics TOTAL (n = 1035) CAI and HCAI (n = 718) HAI (n = 317) p-value
Male sex, n (%) 506 (49) 344 (48) 162 (51) 0.343*
Age, mean (SD) 65 (20) 65 (20) 64 (19) 0.405&
SAPSII, mean (SD) 29 (13) 29 (12) 30 (13) 0.962&
Severity of infection, n (%) 0.922*
Localized infection without SIRS 281 (27) 195 (27) 86 (27)
Sepsis 364 (35) 251 (35) 113 (36)
Severe sepsis 296 (29) 209 (29) 87 (27)
Septic shock 94 (9) 63 (9) 31 (10)
Previous comorbidities, n (%) 671 (65) 460 (64) 211 (67) 0.438*
Chronic hepatic disease, n (%) 22 (2) 18 (3) 4 (1) 0.822$
Chronic renal disease, n (%) 149 (14) 94 (13) 55 (17) 0.072*
Chronic heart failure, n (%) 74 (7) 46 (6) 28 (9) 0.163*
Chronic respiratory disease, n (%) 66 (6) 52 (7) 14 (4) 0.086*
Hematologic disease, n (%) 60 (6) 35 (5) 25 (8) 0.056*
Cancer, n (%) 45 (4) 26 (4) 19 (6) 0.084*
Diabetes, n (%) 204 (20) 144 (20) 60 (19) 0.674*
Atherosclerotic disease, n (%) 242 (23) 168 (23) 74 (23) 0.985*
Immunosuppression, n (%) 221 (21) 137 (19) 84 (27) 0.007*
Karnofsky index<70, n (%) 319 (31) 227 (32) 92 (29) 0.405*
Hospitalization in the previous year, n (%) 413 (40) 239 (33) 174 (55) <0.001*
Previous antibiotic therapy, n (%) 367 (36) 137 (19) 230 (73) <0.001*
Hospital mortality, n (%) 138 (13) 79 (11) 59 (19) 0.001*
CAI – community-acquired infection, HCAI – healthcare-associated infection, HAI – hospital-acquired infection, IQR – Inter-quartile range, SD – Standard deviation,
SOFA – Sepsis-related Organ Failure Assessment, SIRS – Systemic inflammatory response syndrome.
*Pearson Qui-square Test; $ Fisher exact test; & Independent samples t-test.
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different from patients with HAI, with a lower proportion of
immunosuppressed patients (19% vs 27%, p = 0.007), a
lower proportion of hospitalizations in the previous year
(33% vs 55%, p < 0.001) and less likelihood of antibiotic ther-
apy in the last month (19% vs 73%, p < 0.001). Hospital mor-
tality was significantly lower in patients from the
community (CAI or HCAI) than in those with HAI (11% vs
19%, p < 0.001) (Table 1). Of the 718 patients with CAI or
HCAI, 439 (61%) had microbiologic documentation; of
these, 123 were MDR (28%), 104 (85%) with MDR-GN and
41 (33%) with ESKAPE organisms.
From the univariate analysis, age, previous antibiotic ther-
apy, hospitalization in the previous year (from 4 months to
1 year), chronic heart failure, chronic respiratory disease,
atherosclerosis and a Karnofsky index <70 were selected for
multivariate analysis of independent risk factors associated
with infection by MDR pathogens, including infection by
MDR-GN (Table 2). For the ESKAPE group, previous anti-
biotic therapy, hospitalization in the previous year, and a
Karnofsky index <70 were the variables selected for the
multivariate model (Table 2).
Regarding infection by MDR pathogens, the final model
retained age (adjusted OR per category = 1.7, p = 0.001) andhospitalization in the previous year (from 4 months to
1 year) (adjusted OR = 2.0, p = 0.008) (Table 3) as independ-
ent risk factors. The final model for MDR-GN infection also
retained age (adjusted OR per category = 1.5, p = 0.009) and
hospitalization in the previous year (from 4 months to
1 year) (adjusted OR = 1.7, p = 0.048) (Table 3). For
ESKAPE pathogen infection, the final model retained previ-
ous antibiotic therapy (adjusted OR = 7.2, p < 0.001) and
Karnofsky index <70 (adjusted OR = 3.7, p = 0.003)
(Table 3).
Patients with infection by a pathogen belonging to one of
the three MDR groups had a significantly higher rate of in-
adequate antibiotic therapy: 16% in the study population,
46% in the group of patients with infection by MDR patho-
gen, 44% in the group with infection by MDR-GN, and 61%
in the group with an ESKAPE group infection (p < 0.001).
Despite that, median hospital length of stay was similar in
all groups, as were SAPS II and hospital mortality rate
(Table 4).
Discussion
In this study, age >60 years, hospitalization in the previ-
ous year (in the last 4 to12 months), previous antibiotic
therapy (last month) and Karnofsky index <70 were
Table 2 Risk factors for MDR, MDR gram-negatives and ESKAPE group pathogens infection
Variables Total, n (%)
n=718
Microbiological
documentation, n (%) n=439
MDR, n (%)
n=123
Crude
OR
p-
value
MDR-GN, n (%)
n=104
Crude
OR
p-
value
ESKAPE pathogens,
n(%) n=41
Crude
OR
p-
value
Age 1.6* <0.001 1.5* 0.009 1.3* 0.170
≤60 years 271 (38) 166 (38) 33 (27) 30 (28) 13 (32)
61-80 years 250 (35) 157 (36) 44 (36) 37 (36) 13 (32)
>80 years 197 (27) 116 (26) 46 (37) 37 (36) 15 (36)
Male sex 344 (48) 203 (46) 56 (46) 1.1 0.656 45 (43) 0.9 0.542 21 (51) 1.2 0.503
Previous antibiotic therapy 137 (19) 94 (21) 38 (31) 1.9 0.009 30 (29) 1.7 0.033 20 (49) 4.2 <0.001
Hospitalization in the previous year
(4 months - 1 year)
146 (20) 102 (23) 37 (30) 2.1 0.006 29 (28) 1.8 0.031 14 (34) 3.3 0.003
Immunosupression (not meeting
criteria of HCAI)
113 (16) 81 (19) 25 (20) 1.1 0.685 24 (23) 1.5 0.116 10 (24) 1.5 0.306
Chronic hepatic disease 18 (3) 14(3) 4 (3) 0.9 0.818 3 (3) 0.9 0.829 2 (5) 1.7 0.522
Chronic heart failure 46 (6) 27 (6) 13 (11) 2.5 0.026 11 (11) 2.3 0.038 2 (5) 0.8 0.723
Chronic respiratory disease 52 (7) 30 (7) 13 (11) 2.2 0.056 11 (11) 1.9 0.093 4 (10) 1.6 0.439
Chronic haematologic disease 35 (5) 29 (7) 8 (7) 1.0 0.945 5 (5) 0.7 0.444 5 (12) 2.2 0.139
Cancer (not meeting criteria of HCAI) 10 (1) 6 (1) 2 (2) 1.5 0.666 2 (2) 1.6 0.578 0 (0)
Diabetes 144 (20) 96 (22) 32 (26) 1.3 0.291 27 (26) 1.4 0.239 11 (27) 1.4 0.421
Atherosclerosis 168 (23) 105 (24) 40 (33) 1.8 0.017 32 (31) 1.6 0.069 13 (32) 1.5 0.222
Karnofsky index<70 227 (32) 149 (34) 57 (46) 1.8 0.006 44 (42) 1.6 0.046 22 (54) 2.5 0.006
Association of demographic and clinical variables with infection by MDR, MDR gram negatives and ESKAPE pathogens among patients admitted from the community (with community-acquired or healthcare-
associated infections), using logistic regression.
*increase in the odds per category of age; MDR – multi-drug resistant; MDR-GN – multi-drug resistant gram negatives; OR – odds ratio; ESKAPE - Vancomycin-resistant Enterococcus faecium, MRSA, ESBL producing E.
coli and Klebsiella species, Klebsiella pneumonia Carbapenamase-hydrolyzing and MDR Acinectobacter baumannii, Pseudomonas aeruginosa and Enterobacter species.
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Table 3 Independent variables associated with infection by MDR, MDR gram-negatives and pathogens from the ESKAPE group
Variables MDR,
n (%)
n = 123
Adjusted OR CI95% p-value MDR Gram
negatives,
n (%) n = 104
Adjusted OR CI95% p-value ESKAPE
pathogens,
n(%) n= 41
Adjusted OR CI95% p-value
Age 1.7 1.3-2.3 0.001 1.5 1.1-2.1 0.009
≤60 years 33 (27) 30 (28) 13 (32)
61-80 years 44 (36) 37 (36) 13 (32)
>80 years 46 (37) 37 (36) 15 (36)
Previous antibiotic therapy 38 (31) 30 (29) 20 (49) 7.2 3.1-17.0 <0.001
Hospitalization in the previous year (4 months - 1 year) 37 (30) 2.0 1.2-3.4 0.008 29 (28) 1.7 1.0-3.0 0.048 14 (34)
Karnofsky index<70 57 (46) 44 (42) 22 (54) 3.7 1.6-8.6 0.003
Selection of variables significantly and independently associated with infection by a MDR pathogen, MDR gram negative or a pathogen from the ESKAPE group, among the group of patients admitted from the
community (with community or healthcare-associated infection), using multiple logistic regression.
*increase in the odds per category of age; MDR – multi-drug resistant; OR – odds ratio; CI – confidence interval; ESKAPE - Vancomycin-resistant Enterococcus faecium, MRSA, ESBL producing E. coli and Klebsiella species,
Klebsiella pneumonia Carbapenamase-hydrolyzing and MDR Acinectobacter baumannii, Pseudomonas aeruginosa and Enterobacter species.
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with infection by MDR pathogens. These risk factors
were not considered in the definition of risk factors of
HCAI proposed by Friedman et al. Patients with infec-
tion by MDR microorganisms had a significantly higher
rate of inadequate initial antibiotic therapy, but did not
have a longer hospital length of stay or higher hospital
mortality rate. This is probably one of the first studies
containing a thorough description of independent and
significant risk factors associated with infection by
pathogens of the ESKAPE group as well as their impact
regarding inadequate antibiotic therapy, hospital length
of stay and hospital mortality.
In order to define the new group of infections across
community and hospital settings, a definition of all risk
factors for MDR pathogen infections is required. The def-
inition proposed by Friedman et al. [3] is one of the most
used in clinical studies regarding HCAI, but it was devel-
oped for bloodstream infections. Further studies followed,
using similar definitions, but again only for a single focus
of infection or single pathogens. Our study identified add-
itional risk factors for MDR pathogen infection.
Micek et al. [10] performed a retrospective cohort
study of hospitalized patients with pneumonia, and iden-
tified immunocompromised state and hospitalization in
the previous 12 months as risk factors for HCAI. They
found a higher proportion of MDR organisms in the
HCAI group, with a significant association with inappro-
priate antibiotic therapy and hospital mortality rate. One
limitation discussed by the authors was the fact that they
did not evaluate severity-of-illness scores. In the current
study severity scores were considered and they were
similar in all groups, with no significant differences in
hospital mortality rate between groups. Park et al. [5]
also performed a retrospective cohort study on HCAI-
pneumonia, using the Friedman et al. definition and prior
antibiotic therapy in the 30 days before the pneumonia
episode, and found a higher proportion of MDR patho-
gens when compared with community-acquired pneumo-
nia, and a significant association with inappropriate initial
antibiotic therapy. Brito and Niederman [18] performed a
review of all articles published since the American Thor-
acic Society guidelines were published [2], and concluded
that patients at risk of pneumonia by MDR pathogens
were those who had severe illness, were hospitalized in
the past 90 days, had antibiotic therapy in the past
6 months, had poor functional status as defined by activ-
ities of daily living score, and were immunosuppressed,
similar to the risk factors described here.
Wright et al. [19] performed a retrospective cohort
study to determine risk factors for MDR pathogens
among patients in the Emergency Department with
urinary tract infections, and described the following
independent risk factors: age ≥65 years, diabetes,prior use of antibiotics, and urinary catheterization.
Chen et al. [20] studied patients from the community
with bacteremia but with prior hospitalization from
periods of 3–90, 91–180 to up to 181–360 days, and
concluded that the presence of antimicrobial-resistant
bacteria in the past 360 days was an independent risk
factor for antimicrobial-resistant bacteremia, reaffirm-
ing that hospitalization in the previous year repre-
sented a risk factor for MDR pathogen infection.
Pop-Vicas et al. [21], in a 6-year study of patients
with positive cultures for MDR organisms, noted an
increasing prevalence of MDR-GN at admission to a
tertiary-care hospital (positive cultures within the first
48 h after hospital admission). Factors independently
associated with isolation of the resistant organisms
were age ≥65 years, prior antibiotic therapy for
≥14 days and prior residence in a long-term-care
facility.
The current study has the major advantage of being
prospective, with clear and consensual definition of
infection [1]. It included all major foci of infection
that drove patients into hospital care and not only
pneumonia, bacteremia or urinary infection as in
other previous studies. It clearly identified the place
of acquisition and the appropriateness of initial anti-
biotic therapy. Data regarding severity of illness and
the impact of infection by MDR organisms in the ap-
propriateness of initial antibiotic therapy, hospital
length of stay and mortality rate were also investi-
gated. Data collection was performed by a single
trained doctor, and all protocols were completed with
no missing data thus minimizing information bias. All
patients completed follow-up until hospital discharge.
Most importantly, risk factors described in this study
have been previously mentioned in studies restricted
to single focus of infection or pathogen, by other
authors from different parts of the world, suggesting
important external applicability of these conclusions.
The study also has certain limitations that should
be acknowledged. The research was performed in a
single institution and the number of patients from
the community was relatively small. There is accumu-
lating evidence that HCAI seems to be a group
encompassing CAI and HAI, but specific definition of
risk factors are lacking. The diversity of definitions used
has led to diverse findings not comparable between stud-
ies, and therefore not consequential for specific treatment
recommendations.
Implementation of standardized approaches for the
treatment of HCAI is desirable, since failure to recognize
this group of infected patients appears to be associated
with administration of inappropriate antibiotic therapy
in hospitalized patients with serious infection, and may
be related to poor prognosis.
Table 4 Impact of infection by MDR pathogens, including MDR gram-negatives and pathogens from the ESKAPE group, in antibiotic therapy and hospital
outcome
Variables MDR, Non-
MDR,
Non- MDR vs
MDR,
MDR-GN Non-MDR-
GN,
Non-MDR-GN vs MDR-
GN,
ESKAPE
pathogens,
Non-ESKAPE
pathogens,
Non-ESKAPE vs
ESKAPE,
n (%) n (%) p Value n (%) n (%) p Value n (%) n (%) p value
Inadequate ATB therapy 57 (46) 19 (7) <0.001* 46 (44) 30 (10) <0.001* 25 (61) 51 (15) <0.001*
Hospital LOS, median
(IQR)
10 (7–17) 10 (7–16) 0.944# 10 (7–15) 10 (7–17) 0.487# 11 (8–15) 10 (7–17) 0.280#
SAPS II, mean (SD) 32 (13) 30 (13) 0.171& 31 (13) 30 (13) 0.428& 32 (17) 30 (12) 0.373&
Hospital mortality 19 (15) 31 (12) 0.280* 13 (13) 37 (13) 0.928* 9 (22) 41 (12) 0.062*
Comparison of inadequate antibiotic therapy, hospital length of stay, SAPS II and hospital mortality between the group of patients infected with MDR pathogens and those not infected, along with comparison of the
group infected by MDR-GN with those not infected, and the group infected by ESKAPE pathogens and those not infected.
ATB – antibiotherapy, CAI – community-acquired infection, LOS – length of stay, IQR – inter-quartil range, MDR – multi-drug resistant, MDR GN – multi-drug resistant gram negatives, ESKAPE - Vancomycin-resistant
Enterococcus faecium, MRSA, ESBL producing E. coli and Klebsiella species, Klebsiella pneumonia Carbapenamase-hydrolyzing and MDR Acinectobacter baumannii, Pseudomonas aeruginosa and Enterobacter species.
*Pearson Qui-square Test; # Mann–Whitney test, &Students t-test.
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The results of this study suggest that the inclusion of
additional risk factors for MDR pathogen infection in
HCAI definition, namely age >60 years, Karnofsky
index <70, hospitalization in the previous year, and
previous antibiotic therapy, may be clinically benefi-
cial because of early diagnosis and a decrease in the
rate of inadequate antibiotic therapy in these patients.
Further research involving a large number of patients
from different institutions and geographic areas is
warranted to confirm these findings.
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